60 Degrees Pharmaceuticals (SXTP) to Release Earnings on Wednesday

60 Degrees Pharmaceuticals (NASDAQ:SXTP) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($1.24) per share and revenue of $0.32 million for the quarter.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last released its quarterly earnings results on Thursday, May 15th. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.31) by ($0.25). The company had revenue of $0.18 million for the quarter, compared to analyst estimates of $0.15 million. On average, analysts expect 60 Degrees Pharmaceuticals to post $-5 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

60 Degrees Pharmaceuticals Stock Performance

NASDAQ:SXTP opened at $1.39 on Monday. 60 Degrees Pharmaceuticals has a 52 week low of $1.26 and a 52 week high of $12.70. The firm has a 50-day moving average price of $2.04 and a two-hundred day moving average price of $2.33. The firm has a market cap of $2.04 million, a price-to-earnings ratio of -0.03 and a beta of 2.71.

Analysts Set New Price Targets

A number of analysts recently commented on SXTP shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Tuesday, July 29th. Wall Street Zen cut 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th. Finally, Ascendiant Capital Markets increased their price target on shares of 60 Degrees Pharmaceuticals from $5.80 to $7.00 and gave the company a “buy” rating in a research report on Monday, June 2nd.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.